Cost-effectiveness analysis of 20-valent anti-pneumococcal vaccination in the Spanish pediatric population [0.03%]
西班牙儿童群体中肺炎球菌疫苗接种的20价成本效益分析
Franciso Álvarez García,Federico Martinón-Torres,Valentín Pineda et al.
Franciso Álvarez García et al.
Objectives: We evaluated the cost-effectiveness of implementingdifferent pneumococcal conjugate vaccines (PCV) - 20-valent (PCV20; 3 + 1), 13-valent(PCV13; 2 + 1), and 15-valent (PCV15; 2 + 1) - into the Spanish pediatric...
Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers [0.03%]
理解低风险癌症经济学评价的生存上限及开展和评估经济评价的能力
Xuanqian Xie,Ishita Joshi,Myra Wang et al.
Xuanqian Xie et al.
Background: In most developed countries, overall survival rates for low-riskcancers (e.g. localized prostate and thyroid cancer) are comparable tothose of the general population. The general population's survival rate may...
Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C [0.03%]
阿达格拉西单药或联合西妥昔单抗治疗KRAS G12C突变型结直肠癌患者的成本效益分析
Ruihong Yao,Yao Yao,Xue Teng et al.
Ruihong Yao et al.
Objectives: This study evaluates the cost-effectiveness of adagrasib plus cetuximab in contrast to adagrasib monotherapy in treating colorectal cancer (CRC) patients with mutated KRASG12C from the perspective of healthcar...
Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA [0.03%]
美国索托拉西布联合帕尼单抗治疗KRAS G12C突变型难治性结直肠癌的成本效益分析
Tong Liu,Yao Yao,Xue Teng et al.
Tong Liu et al.
Background: This studyevaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standardcare in the treatment of refractory colorectal cancer (CRC) with mutated KRASG12Cfrom the perspective of healthca...
Methodological approaches in the economic evaluation of prognostic and predictive Companion diagnostics: a systematic scoping review [0.03%]
伴随诊断预后和预测的经济学评估方法研究：系统综述式的循证评价
Tuukka Hakkarainen,Haavisto Ira,Leskelä Riikka-Leena
Tuukka Hakkarainen
Introduction: This systematic scoping review aimed to identify and analyze current methodological approaches used in model-based economic evaluations (EEs) of prognostic and predictive companion diagnostics (pCDx), highli...
Adherence to asthma and COPD therapies in low- and middle-income countries: a narrative review [0.03%]
发展中国家哮喘和慢阻肺治疗依从性的叙事综述
Vaibhav Gaur,Alessandra Sorano,Himanshu Sankrityayan et al.
Vaibhav Gaur et al.
Introduction: In low-income and middle-income countries (LIMCs), defined based on the World Bank classification, non-adherence to respiratory therapies contributes to increasing mortality and morbidity due to chronic resp...
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair [0.03%]
分层加速术后康复路径在腹壁疝修补术中应用及实施效果研究
James Espeleta,Sunitha Singh,Ethan Augustine et al.
James Espeleta et al.
Introduction: Enhanced recovery after surgery (ERAS) pathways are widely adopted in both major and minimally invasive surgeries. However, ERAS pathway implementation in ventral hernia repair (VHR) surgery remains an area ...
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and shiga prefecture [0.03%]
日本66-84岁成人接种20价肺炎球菌结合疫苗的卫生和经济影响及评估其在京都市的应用效果
Tomoyuki Suzuki,Yoko Hirano,Kazumasa Kamei et al.
Tomoyuki Suzuki et al.
Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We eval...
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation [0.03%]
奥希替尼与达可替尼作为EGFR突变阳性晚期非小细胞肺癌一线治疗的成本效用分析
Lili Su,Xiangyu Zhang,Mengrong Li et al.
Lili Su et al.
Objective: To evaluate the cost-effectiveness of osimertinib compared to dacomitinib for advanced non-small cell lung cancer with EGFR mutation from the perspective of China's health system. ...
Determinants of cancer drug prices in Germany and France: a multiple regression analysis [0.03%]
德国和法国抗癌药物价格决定因素：多元回归分析
Nethra Subramanian,Aadhav Subramanian
Nethra Subramanian
Background: Higher prices for drugs targeting rarer cancers may be justified, but the extent remains uncertain. This research analyses the determinants of cancer drug prices in Germany and France. ...